Cargando…

Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein

BACKGROUND: Phytochemical-mediated alterations in P-glycoprotein (P-gp) activity may result in herb-drug interactions by altering drug pharmacokinetics. Shengmai-san, a traditional Chinese herbal medicine composed by Panax Ginseng, Ophiopogon Japonicus, and Schisandra Chinensis, is routinely being u...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yan, Zhou, Yuanyuan, Zhang, Jingwei, Rao, Tai, Zhou, Lijun, Xing, Rong, Wang, Qian, Fu, Hanxu, Hao, Kun, Xie, Lin, Wang, Guangji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055595/
https://www.ncbi.nlm.nih.gov/pubmed/24922060
http://dx.doi.org/10.1371/journal.pone.0098717
_version_ 1782320684389629952
author Liang, Yan
Zhou, Yuanyuan
Zhang, Jingwei
Rao, Tai
Zhou, Lijun
Xing, Rong
Wang, Qian
Fu, Hanxu
Hao, Kun
Xie, Lin
Wang, Guangji
author_facet Liang, Yan
Zhou, Yuanyuan
Zhang, Jingwei
Rao, Tai
Zhou, Lijun
Xing, Rong
Wang, Qian
Fu, Hanxu
Hao, Kun
Xie, Lin
Wang, Guangji
author_sort Liang, Yan
collection PubMed
description BACKGROUND: Phytochemical-mediated alterations in P-glycoprotein (P-gp) activity may result in herb-drug interactions by altering drug pharmacokinetics. Shengmai-san, a traditional Chinese herbal medicine composed by Panax Ginseng, Ophiopogon Japonicus, and Schisandra Chinensis, is routinely being used for treating various coronary heart diseases. In our previous studies, Schisandra Lignans Extract (SLE) was proved as a strong P-gp inhibitor, and herein, the compatibility of Shengmai-san was studied by investigating the influence of SLE on the pharmacokinetics of the ginsenosides from the perspective of P-gp. METHODOLOGY: Pharmacokinetic experiments were firstly performed based on in vitro uptake, efflux and transport experiments in Caco-2, LLC-PK1 wild-type and MDR1-overexpressing L-MDR1 cells. During the whole experiment, digoxin, a classical P-gp substrate, was used as a positive control drug to verify the cells used are the valid models. Meanwhile, the effects of SLE on the pharmacokinetics of ginsenosides were further investigated in rats after single-dose and multi-dose of SLE. RESULTS AND CONCLUSIONS: The efflux ratios of ginsenoside Rb2, Rc, Rg2, Rg3, Rd and Rb1 were found more than 3.5 in L-MDR1 cells and can be decreased significantly by verapamil (a classical P-gp inhibitor). Contrarily, the efflux ratios of other ginsenosides (Rh1, F1, Re, and Rg1) were lower than 2.0 and not affected by verapamil. Then, the effects of SLE on the uptake and transport of ginsenosides were investigated, and SLE was found can significantly enhance the uptake and inhibit the efflux ratio of ginsenoside Rb2, Rc, Rg2, Rg3, Rd and Rb1 in Caco-2 and L-MDR1 cells. Besides, In vivo experiments showed that single-dose and multi-dose of SLE at 500 mg/kg could increase the area under the plasma concentration time curve of Rb2, Rc and Rd significantly without affecting terminal elimination half-time. In conclusion, SLE could enhance the exposure of ginsenosides Rb2, Rc, Rg2, Rg3, Rd and Rb1 significantly.
format Online
Article
Text
id pubmed-4055595
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40555952014-06-18 Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein Liang, Yan Zhou, Yuanyuan Zhang, Jingwei Rao, Tai Zhou, Lijun Xing, Rong Wang, Qian Fu, Hanxu Hao, Kun Xie, Lin Wang, Guangji PLoS One Research Article BACKGROUND: Phytochemical-mediated alterations in P-glycoprotein (P-gp) activity may result in herb-drug interactions by altering drug pharmacokinetics. Shengmai-san, a traditional Chinese herbal medicine composed by Panax Ginseng, Ophiopogon Japonicus, and Schisandra Chinensis, is routinely being used for treating various coronary heart diseases. In our previous studies, Schisandra Lignans Extract (SLE) was proved as a strong P-gp inhibitor, and herein, the compatibility of Shengmai-san was studied by investigating the influence of SLE on the pharmacokinetics of the ginsenosides from the perspective of P-gp. METHODOLOGY: Pharmacokinetic experiments were firstly performed based on in vitro uptake, efflux and transport experiments in Caco-2, LLC-PK1 wild-type and MDR1-overexpressing L-MDR1 cells. During the whole experiment, digoxin, a classical P-gp substrate, was used as a positive control drug to verify the cells used are the valid models. Meanwhile, the effects of SLE on the pharmacokinetics of ginsenosides were further investigated in rats after single-dose and multi-dose of SLE. RESULTS AND CONCLUSIONS: The efflux ratios of ginsenoside Rb2, Rc, Rg2, Rg3, Rd and Rb1 were found more than 3.5 in L-MDR1 cells and can be decreased significantly by verapamil (a classical P-gp inhibitor). Contrarily, the efflux ratios of other ginsenosides (Rh1, F1, Re, and Rg1) were lower than 2.0 and not affected by verapamil. Then, the effects of SLE on the uptake and transport of ginsenosides were investigated, and SLE was found can significantly enhance the uptake and inhibit the efflux ratio of ginsenoside Rb2, Rc, Rg2, Rg3, Rd and Rb1 in Caco-2 and L-MDR1 cells. Besides, In vivo experiments showed that single-dose and multi-dose of SLE at 500 mg/kg could increase the area under the plasma concentration time curve of Rb2, Rc and Rd significantly without affecting terminal elimination half-time. In conclusion, SLE could enhance the exposure of ginsenosides Rb2, Rc, Rg2, Rg3, Rd and Rb1 significantly. Public Library of Science 2014-06-12 /pmc/articles/PMC4055595/ /pubmed/24922060 http://dx.doi.org/10.1371/journal.pone.0098717 Text en © 2014 Liang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Liang, Yan
Zhou, Yuanyuan
Zhang, Jingwei
Rao, Tai
Zhou, Lijun
Xing, Rong
Wang, Qian
Fu, Hanxu
Hao, Kun
Xie, Lin
Wang, Guangji
Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein
title Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein
title_full Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein
title_fullStr Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein
title_full_unstemmed Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein
title_short Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein
title_sort pharmacokinetic compatibility of ginsenosides and schisandra lignans in shengmai-san: from the perspective of p-glycoprotein
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055595/
https://www.ncbi.nlm.nih.gov/pubmed/24922060
http://dx.doi.org/10.1371/journal.pone.0098717
work_keys_str_mv AT liangyan pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT zhouyuanyuan pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT zhangjingwei pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT raotai pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT zhoulijun pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT xingrong pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT wangqian pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT fuhanxu pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT haokun pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT xielin pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein
AT wangguangji pharmacokineticcompatibilityofginsenosidesandschisandralignansinshengmaisanfromtheperspectiveofpglycoprotein